Business

Mass. Movers

ArQule’s lead drug faces hurdle on dosing

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.
Joanne Rathe/Globe Staff/File 2007
ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Woburn-based ArQule Inc. and its development partner, Daiichi Sankyo Co., said that they will implement a lower dose of their treatment for hard-to-treat cases of liver cancer, Dow Jones reported. The change was recommended by a Food and Drug Administration panel following increased incidences of low white blood cell counts. The announcement is the latest hurdle for tivantinib, ArQule’s lead product candidate.